

Leprosy Review Index

VOLUME 69 (1998)

	PAGE
A field trial of detection and treatment of nerve function impairment in leprosy – report from national POD pilot project. J. JIANG, J. M. WATSON, G. C. ZHANG & X. Y. WEI	367
ANDERSON, A. M., <i>see</i> BRANDSMA, J. W.	257
ANTIA, N. H., <i>see</i> SINGH, N.	246
ARORA, V. K., <i>see</i> SINGH, N.	145
ARUNTHATHI, S., EBENEZER, L. & KUMUDA, C. Reversal reaction, nerve damage and steroid therapy in three multibacillary HIV positive patients	173
ARUNTHATHI, S., <i>see</i> , SUNEETHA, S.	351, 358
BAHTIA, A., <i>see</i> SINGH, N.	145
BAINSON, K. A. & VAN DEN BORNE, B. Dimensions and process of stigmatization in leprosy	341
BASKIN, G. B., <i>see</i> GORMUS, B. J.	6, 21, 235
BHATTACHARYA, S. N., <i>see</i> SINGH, N.	145
BIRDI, T. J., <i>see</i> SINGH, N.	246
BLANCHARD, J. L., <i>see</i> GORMUS, B. J.	235
BOHM, R. P. , <i>see</i> GORMUS, B. J.	6, 235
BOOBIS, S. Journals on the Net: some sites reviewed	294
BRANDSMA, J. W., VAN BRAKEL, W. H., ANDERSON, A. M., KORTENDIJK, A. J., GURUNG, K. S. & SUNWAR, S. K. Intertester reliability of manual muscle strength testing in leprosy patients	257
BRENNAN, P., <i>see</i> ROCHE, P.	151
BRITTON, W. J. The management of leprosy reversal reactions	225
BULMAKERS, L. <i>see</i> LEVER, P.	122
BUTLIN, C. R., <i>see</i> WEIR, R. E..	279
CARDO, P. P., <i>see</i> FIALLO, P.	376
CHACKO, C. J. G., <i>see</i> , SUNEETHA, S.	351, 358
CHANDI, S., <i>see</i> , SUNEETHA, S.	351
CHANDRASHEKAR, S., <i>see</i> SINGH, N.	246
CREE, I. A. & CAIRNS SMITH, W. Leprosy transmission and mucosal immunity: towards eradication?	112
CHO, S.-N., <i>see</i> GORMUS, B. J.	6
Choosing the decolourizer and its strength to stain <i>Mycobacterium leprae</i> . DOES IT ACTUALLY MATTER? R. DE SOLDENHOFF, M. HATTA AND T. WELING SIRO	128
Commentary. Is it safe to shorten multidrug therapy for lepromatous (LL and BL) leprosy to 12 months? M. WATERS	110
CAIRNS SMITH, W., <i>see</i> CREE, I. A.	112
DATE, A., JOHN, G. T., THOMAS, P. P. & JACOB, C. K. Leprosy and renal transplantation.	40
DATE, A., <i>see</i> SUNEETHA, S.	358
DE JONG, J. T. V. M., <i>see</i> VAN DE WEG, N.	382
DE SOLDENHOFF, R., HATTA, M. & WELING SIRO, T. Choosing the decolourizer and its strength to stain <i>Mycobacterium leprae</i> . DOES IT ACTUALLY MATTER?	128
Dimensions and process of stigmatization in leprosy. K. A. BAINSON & B. VAN DEN BORNE	341
DOCKRELL, H., <i>see</i> ROCHE, P.	151
DOCKRELL, H. M., <i>see</i> WEIR, R. E..	279
DUERKSON, F. Surgery of common paralytic conditions.	390
EBENEZER, L., <i>see</i> ARUNTHATHI, S.	173

Ebenso, B. E. Seizures following chloroquine treatment of type II lepra reaction: a case report	178
Evaluation of a sustained 7-year health education campaign on leprosy in Rufiji District, Tanzania. J. Van Den Broek, J. O'Donoghue, A. Ishengoma, H. Masao & M. Mbega	57
Experimental leprosy in rhesus monkeys: transmission, susceptibility, clinical and immunological findings. B. Gormus, K. Xu, G. B. Baskin, L. N. Martin, R. P. Bohm, J. L. Blanchard, P. A. Mack, M. S. Ratterree, W. M. Meyers & G. P. Walsh	235
Explanatory models and help-seeking behaviour of leprosy patients in Adamawa State, Nigeria N. Van De Weg, E. B. Post, R. Lucassen, J. T. V. M. De Jong and J. Van Den Broek	382
Failbus, S. S., <i>see</i> Weir, R. E.	279
Fiallo, P., Travaglino, C., Nunzi, E. & Cardo, P. P. (β 2-Glycoprotein I dependence of anti-cardiolipin antibodies in multibacillary leprosy patients	376
Fine-needle aspiration cytology of lepromatous leprosy N. Singh, A. Bhatia, V. K. Arora & S. N. Bhattacharya	145
Fixed drug eruption due to rifampin. S. S. John	397
Future role of leprosy training and/or research institutions. ALERT, February 25–26, 1998. P. Saunderson	160
Gerone, P. J., <i>see</i> Gormus, B. J.	21
Gillis, T. P., <i>see</i> Gormus, B. J.	21
Gormus, B. J., Baskin, G. B., Xu, K., Bohm, R. P., Mack, P. A., Ratterree, M. S., Cho, S.-N., Meyers, W. M. & Walsh, P. Protective immunization of monkeys with BCG or BCC plus heat-killed <i>Mycobacterium leprae</i> : clinical results	6
Gormus, B. J., Murphey-Corb, Martin, L. N., Baskin, G. B., Mack, P. A., Xu, K., Ratterree, M. S., Gerone, P. J., Scollard, D. M. & Gillis, T. P. Impaired responses to <i>Mycobacterium leprae</i> antigens in rhesus monkeys experimentally inoculated with simian immunodeficiency virus and <i>M. leprae</i>	21
(2-Glycoprotein I dependence of anti-cardiolipin antibodies in multibacillary leprosy patients P. Fiallo, C. Travaglino, E. Nunzi & P. P. Cardo	376
Gormus, B., Xu, K., Baskin, G. B., Martin, L. N., Bohm, R. P., Blanchard, J. L., Mack, P. A., Ratterree, M. S., Meyers, W. M. & Walsh, G. P. Experimental leprosy in rhesus monkeys: transmission, susceptibility, clinical and immunological findings	235
Green, A. T. & Jochem, K. Sustaining leprosy services in the changing context of health sector reform	134
Gurung, K. S., <i>see</i> Brandsma, J. W.	257
Hatta, M., <i>see</i> De Soldenhoff, R.	128
Health systems research in leprosy control – what contributions can it make? P. Lever, L. Bulmakers, P. Zwanikken and P. Saunderson	122
Histological studies in primary neuritic leprosy: changes in the apparently normal skin. S. Suneetha, A. Arunthathi, S. Chandi, N. Kurian & C. J. G. Chacko	351
Histological studies in primary neuritic leprosy: changes in the nasal mucosa. S. Suneetha, S. Arunthathi, A. Job, A. Date, N. Kurian & C. J. G. Chacko	358
Impaired responses to <i>Mycobacterium leprae</i> antigens in rhesus monkeys experimentally inoculated with simian immunodeficiency virus and <i>M. leprae</i> B. J. Gormus, M. Murphy-Corb, L. N. Martin, G. B. Baskin, P. A. Mack, Keyu Xu M. S. Ratterjee, P. J. Gerone, D. M. Scollard & T. P. Gillis	21
Indications for surgery in leprosy. M. Virmond	297
International Leprosy Congress, Beijing, 7–12 September 1998: working toward a world without leprosy. A. C. McDougall	338
Intertester reliability of manual muscle strength testing in leprosy patients. J. W. Brandsma, W. H. Van Brakel, A. M. Anderson, A. J. Kortendijk, K. S. Gurung & S. K. Sunwar	257
<i>In vitro</i> studies on extracellular matrix production by <i>M. leprae</i> infected murine neurofibroblasts. N. Singh, T. J. Birdi, S. Chandrashekar & N. H. Antia	246
Ishengoma, A., <i>see</i> Van Den Broek, J.	57
Is there a microbiology rationale for single-dose treatment of leprosy? V. M. Katoch	2
Jacob, C. K., <i>see</i> Date, A.	40
Ji, B. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months	106
Jiang, J., Watson, J. M., Zhang, G. C. & Wei, X. Y. A field trial of detection and treatment of nerve function impairment in leprosy – report from national POD pilot project	367

J. JIANG, J. M. WATSON, G. C. ZHANG & X. Y. WEI	367
JOB, A., <i>see</i> SUNEETHA, S.	358
JOCHEM, K., <i>see</i> GREEN, A. T.	134
JOHN, G. T., <i>see</i> DATE, A.	40
JOHN, S. S. Fixed drug eruption due to rifampin	397
Journals on the Net: some sites reviewed. SUSAN BOOBIS	294
KATOCH, V. M. Is there a microbiology rationale for single-dose treatment of leprosy?	2
KORTENDIJK, A. J., <i>see</i> BRANDSMA, J. W.	257
KUMUDA, C., <i>see</i> ARUNTHATHI, S.	173
KURIAN, N., <i>see</i> SUNEETHA, S.	358
LADHANI S. Leprosy in Pakistan – Student Elective Report.	164
Leprosy and disability control in the Guera Prefecture of Chad, Africa: do women have access to leprosy control services? J. SCHFER	267
Leprosy and renal transplantation. ANAND DATE, G. T. JOHN, P. P. THOMAS & C. K. JACOB	40
Leprosy in Pakistan - Student Elective Report. S. Ladhani	164
Leprosy transmission and mucosal immunity: towards eradication? I. A. CREE AND W. CAIRNS SMITH	112
LETTERS TO THE EDITOR	
NAIK, S. S. & GANAPATI, R.	183
NAMISATO, N.	82
PATKI, A. H.	401
RAMU, G.	78
REVANKAR, C. R.	305
SALAÑA, A. & CHUHAN, G.	87
SAUNDERSON, P. & GABRE, S.	185
SCHREUDER, P. A. M.	184
SEBOKA, G., SAUNDERSON, P. & CURRIE, H.	182
SMITH, W. C. S., FINE, P. & WARNDORFF, D. K.	77
SINGH, G.	400
LEVER, P., BULMAKERS, L., ZWANIKKEN, P. & SAUNDERSON, S. Health systems research in leprosy control – what contributions can it make?	122
LUCASSEN, R., <i>see</i> VAN DE WEG, N.	382
MACK, P. A., <i>see</i> GORMUS, B. J.	6, 21, 235
MARTIN, L. N., <i>see</i> GORMUS, B. J.	21, 235
MASAO, H., <i>see</i> VAN DEN BROEK, J.	57
MBEGA, M., <i>see</i> VAN DEN BROEK, J.	57
McDOUGALL, A. C. International Leprosy Congress, Beijing, 7–12 September 1998: working toward a world without leprosy	338
MEYERS, W. M., <i>see</i> GORMUS, B. J.	6, 235
MURPHEY-CORB, M., <i>see</i> GORMUS, B. J.	21
<i>Mycobacterium w</i> immunotherapy in leprosy. C. WHITTY	222
NEUPAIN, K. D., <i>see</i> WEIR, R. E.	279
NUNZI, E., <i>see</i> FIALLO, P.	376
O'DONOGHUE, J., <i>see</i> VAN DEN BROEK, J.	57
PALANDE, D. D. The promise of surgery, its scope and limitations in leprosy	168
POST, E. B., <i>see</i> VAN DE WEG, N.	382
Progress in research towards a world without leprosy. Report of a WHO meeting in Ethiopia, February 1998. P. ROCHE, H. DOCKRELL & P. BRENNAN	151
Protective immunization of monkeys with BCG or BCC plus heat-killed <i>Mycobacterium leprae</i> : clinical results. B. J. GORMUS, G. B. BASKIN, KEYU XU, R. P. BOHM, P. A. MACK, M. S. RATTERREE SANG-NAE CHO, W. M. MEYERS & P. WALSH	6
RATTERREE, M. S., <i>see</i> GORMUS, B. J.	6, 21, 235
Reversal reaction, nerve damage and steroid therapy in three multibacillary HIV positive patients. S. ARUNTHATHI, L. EBENEZER AND C. KUMUDA	173
ROCHE, P., DOCKRELL, H. & BRENNAN, P. Progress in research towards a world without leprosy. Report of a WHO meeting in Ethiopia, February 1998	151

SAUNDERSON, P. <i>see</i> LEVER, P.	122
SAUNDERSON, P. Future role of leprosy training and/or research institutions. ALERT, February 25–26, 1998.	160
SCHFER, J. Leprosy and disability control in the Guera Prefecture of Chad, Africa: do women have access to leprosy control services?	267
SCOLLARD, D. M., <i>see</i> GORMUS, B. J.	21
Sustaining leprosy services in the changing context of health sector reform. A. T. GREEN AND K. JOCHEM	134
Seizures following chloroquine treatment of type II lepra reaction: a case report. B. E. EBENSO	178
SINGH, N., BHATIA, A., ARORA, V. K. & BHATTACHARYA, S. N. Fine-needle aspiration cytology of lepromatous leprosy	145
SINGH, N., BIRDI, T. J., CHANDRASHEKAR, S. & ANTIA, N. H. <i>In vitro</i> studies on extracellular matrix production by <i>M. leprae</i> infected murine neurofibroblasts.	246
SUNWAR, S. K., <i>see</i> BRANDSMA, J. W.	257
SUNEETHA, S., ARUNTHATHI, A., CHANDI, S., KURIAN, N. & CHACKO, C. J. G. Histological studies in primary neuritic leprosy: changes in the apparently normal skin	351
SUNEETHA, S., ARUNTHATHI, S., JOB, A., DATE, A., KURIAN, N. & CHACKO, C. J. G. Histological studies in primary neuritic leprosy: changes in the nasal mucosa	358
Surgery of common paralytic conditions. F. DUERKSON.	390
TEN HAM P. G. B., <i>see</i> WITTENHORST, B.	46
The management of leprosy reversal reactions. W. J. BRITTON	225
The National Leprosy Control Programme of Zimbabwe: a data analysis, 1983–1992. B. WITTENHORST, M. L. VREE, P. B. G. TEN HAM & J. P. VELEMA	46
The promise of surgery, its scope and limitations in leprosy. D. D. PALANDE	168
THOMAS, P. P., <i>see</i> DATE, A.	40
TRAVAGLINO, E., <i>see</i> FIALLO, P.	376
Use of a whole blood assay to monitor the immune response to mycobacterial antigens in leprosy patients: a predictor for type I reaction onset? R. E. WEIR, C. R. BUTLIN, K. D. NEUPANE, S. S. FAILBUS & H. M. DOCKRELL	279
VAN BRAKEL, W. H., <i>see</i> BRANDSMA, J. W.	257
VAN DE WEG, N., POST, E. B., LUCASSEN, R., DE JONG, J. T. V. M. & VAN DEN BROEK, J. Explanatory models and help-seeking behaviour of leprosy patients in Adamawa State, Nigeria	382
VAN DEN BORNE, B., <i>see</i> BAINSON, K. A.	341
VAN DEN BROEK, J., O'DONOGHUE, J., ISHENOGOMA, A., MASAO, H. & MBEGA, M. Evaluation of a sustained 7-year health education campaign on leprosy in Rufiji District, Tanzania	57
VAN DEN BROEK, J., <i>see</i> VAN DE WEG, N.	382
VELEMA, J. P., <i>see</i> WITTENHORST, B.	46
VIRMOND, M. Indications for surgery in leprosy	297
VREE, P. B., <i>see</i> WITTENHORST, B.	46
WALSH, P., <i>see</i> GORMUS, B. J.	6, 235
Why multidrug therapy for multibacillary leprosy can be shortened to 12 months. B. Ji	106
WATERS, M. Commentary. Is it safe to shorten multidrug therapy for lepromatous (LL and BL) leprosy to 12 months?	110
WATSON, J. M., <i>see</i> JIANG, J.	367
WEI, X. Y., <i>see</i> JIANG, J.	367
WEIR, R. E., BUTLIN, C. R., NEUPANE, K. D., FAILBUS, S. S. & DOCKRELL, H. M. Use of a whole blood assay to monitor the immune response to mycobacterial antigens in leprosy patients: a predictor for type I reaction onset?	279
WELING SIRO, T., <i>see</i> DE SOLDENHOFF, R.	128
WHITTY, C. <i>Mycobacterium w</i> immunotherapy in leprosy	222
WITTENHORST, B., VREE, M. L., TEN HAM, P. B. G. & VELEMA, J. P. The National Leprosy Control Programme of Zimbabwe: a data analysis, 1983–1992	46
XU, K., <i>see</i> GORMUS, B. J.	6, 21, 235
ZHANG, G. C., <i>see</i> JIANG, J.	367
ZWANIKKEN, P. <i>see</i> LEVER, P.	122